Physician profile
Natalia Chaimowitz
NPI 1306265590
$56,001.37
in general payments reported to CMS, 2019-2025
10 companies · $16K in 2025
The $16K reported for 2025 was more than what 91% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.05 · 2022: $121 · 2023: $12K · 2024: $28K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Consulting Fee: $17K · Travel and Lodging: $7,150 · Food and Beverage: $2,377 · Honoraria: $1,800 · Education: $52.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,742.00 |
| Consulting Fee | $16,740.00 |
| Travel and Lodging | $7,149.58 |
| Food and Beverage | $2,377.05 |
| Honoraria | $1,800.00 |
| Education | $52.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $14,869.32 | 2023-2025 | Xembify |
| Amgen INC. | $14,137.97 | 2024-2025 | Actimmune |
| Sumitomo Pharma America, INC. | $9,597.45 | 2023 | Rethymic |
| Pharming Healthcare, INC. | $5,926.84 | 2022-2024 | Joenja |
| Csl Behring | $5,346.88 | 2019-2025 | Hizentra |
| Genzyme Corporation | $2,236.09 | 2024 | |
| Horizon Therapeutics Plc | $1,821.80 | 2023 | Actimmune |
| Grifols Shared Services North America, INC. | $1,710.00 | 2025 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $192.23 | 2022-2023 | Hyqvia |
| Sobi, INC | $162.79 | 2023-2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalia Chaimowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.